生白合剂对肺癌化疗后骨髓抑制的疗效观察

Clinical Observation of Shengbai Oral Solution on Prevention of Neutropenia Induced by Chemotherapy for Lung Cancers

目的:观察生白合剂对肺癌化疗后骨髓抑制的保护作用。方法:将191例使用含铂二联(化疗药物剂量:紫杉醇脂质体175 mg/m^2,依托泊苷120 mg/m^2或100 mg/m^2,顺铂75 mg/m^2,D1,卡铂AUC=6)的Ⅳ期肺癌患者随机分为处理组(95例)和对照组(96例)。处理组当天开始口服生白合剂,一次40 mL,3次/d,连服4 d;第5 d开始剂量减半服用,一次20 mL,3次/d,连服4 d;共计8 d。每3 d复查血常规。对照组化疗后未预防性使用生白合剂。结果:处理组Ⅱ度及Ⅱ度以上骨髓抑制发生率8.42%,显著低于对照组的22.9%(χ~2=8.52,P<0.01);处理组和对照组人均集落刺激因子(G-CSF)用量分别为(79/95)支和(163/96)(t=3.566,P<0.01)。结论:生白合剂可预防肺癌化疗药物引起的骨髓抑制,减少集落刺激因子的用量。

Objective To observe the effect of Shengbai oral solution on protection of neueropemia induced by chemotherapy of lung cancer.Methods Total 191 patients of advanced lung cancer treated with platinumcontaining chemotherapy regimen(dose of chemotherapy:paclitaxel liposome,175 mg/m2;etoposide,120 mg/m2 or 100 mg/m2;cisplatin,75 mg/m2;carboplatin,AUC=6)were randomized into two groups.Treatment group(95 patients)administered with Shengbai oral solution,40 mL three times a day continued 3 days then decreased dose to 20ml continued 3 days,beginning in the first day after chemotherapy.Blood routines were tested every three days.Control group(96 patients)did not use Shengbai oral solution after chemotherapy.The myelosuppression level and the quantity of granulocytic colony stimulating factor(G-CSF)being used were investigated.Results The rate ofⅢandⅣmyelosuppression was 8.42%in treatment group,which was significant lower than in control group of 23.5%(χ2=8.52,P<0.01).The quantity of use of G-CSF in treatment group was also significant lower than that in control group(t=3.566,P<0.01).Conclusion Shengbai oral solution can decrease bone marrow suppression caused by chemotherapy in lung cancer patients,reduce the using amount of G-CSF.